Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials

BACKGROUND: This report evaluated the cardiovascular safety of the amylin analog pramlintide—an existing diabetes injectable treatment—by comparing relevant cardiovascular adverse events (AEs) reported in previous phase 3 and 4 clinical trials among patients receiving pramlintide and those receiving...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrmann, Kathrin, Zhou, Ming, Wang, Andrew, de Bruin, Tjerk W. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471856/
https://www.ncbi.nlm.nih.gov/pubmed/28702246
http://dx.doi.org/10.1186/s40842-016-0030-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471856/
https://www.ncbi.nlm.nih.gov/pubmed/28702246
http://dx.doi.org/10.1186/s40842-016-0030-z

Ejemplares similares